News Related to body weight reduction

Biotech M&A Targets Focus on Late-Stage GLP-1, Oncology and CNS Assets

Apr 02, 2026

Pharmaceutical M&A is shifting toward late-stage clinical assets with proven human data, particularly in GLP-1 obesity drugs, oncology, and central nervous system disorders. Companies like Viking Therapeutics, Structure Therapeutics, and Revolution Medicines represent compelling acquisition targets with advanced clinical programs. This trend reflects industry prioritization of de-risked assets that can accelerate commercialization pathways.

Genentech Reports Positive Phase II Results for Petrelintide in Obesity Trial

Mar 06, 2026

Genentech announced positive Phase II results for petrelintide, showing up to 10.7% mean weight loss versus 1.7% placebo at week 42 in people with overweight and obesity, with placebo-like tolerability.

Roche Advances Obesity Drug Trial and Receives FDA Decision Date for Breast Cancer Therapy

Mar 06, 2026

Roche announced positive phase II results for obesity drug petrelintide showing 10.7% weight reduction, while the FDA set a December 18 decision date for breast cancer drug giredestrant.